Ryan G. Email & Phone Number

Northern California / San Francisco Bay Area

*Launch and establish Duvyzat (Givinostat), a pan HDAC inhibitor indicated for the treatment of Duchenne Muscular Dystrophy in patients > 6 years of age.*Educate Pediatric Specialists and Key Neuromuscular Accounts on Duvyzat (givinostat) an emerging treatment option for patients with DMD, further broadening treatment options for patients at any stage of disease progression.*Collaborate cross function to build awareness and represent Italfarmaco & ITF Therapeutics among the DMD patient/caregiver community.*Collaborate internally and externally to identify and develop value initiatives to Key Accounts and advance engagement with specialists, mid-level providers and ancillary care teams.*Support and Educate Key Accounts/Ancillary Staff on the prescribing process for Duvyzat; Collaborate appropriately to support Access/Reimbursement to ensure seamless 1st experience and expand utilization of Duvyzat for appropriate DMD patients.*Identify and support patient/caregiver associations to broaden disease and product education, further advancing awareness for ITF Therapeutics’s mission to support the DMD patient/caregiver community.*Support KOL National Congresses and Identify Local Conferences in the community; Appropriately collaborate cross function to maximize opportunity to engage and further relationships with KOL’s on the clinical benefits and rationale of starting Duvyzat as early as possible in patients with DMD.*Implement strategic speaker programming to support Disease and Product education of Duvyzat within assigned Key Accounts, MD’s, mid-levels, and ancillary care teams.

N Ca | Nv | Or | Wa | Hi | Ak

Lead and establish Mirum as the foremost authority in the field of cholestatic liver disease by spearheading the promotion and recognition of Livmarli (Maralixibat), the first FDA-approved treatment for cholestatic pruritus of Alagille Syndrome in patients over 1 year of age. Conduct comprehensive pre-approval profiling of key accounts and transplant hepatologists within a six- state territory spanning North California, Nevada, Washington, Oregon, Alaska, and Hawaii. Take charge of Key Accounts, Centers of Excellence, and clinical trial sites/Principal Investigators (PIs). Foster the development of Key Opinion Leaders (KOLs) within the region, actively engaging with them and enhancing corporate relationships to establish and strengthen Mirum's brand presence in the cholestatic liver disease field. Collaborate with prominent regional patient and caregiver advocacy groups to drive awareness and knowledge about Livmarli (Maralixibat), ultimately improving patient outcomes and increasing understanding of the condition.Undertake the responsibility of launching comprehensive disease education initiatives and conducting thorough account profiling for Alagille Syndrome, an autosomal dominant form of cholestatic liver disease. Alagille Syndrome manifests across a wide spectrum, characterized by JAG1 and NOTCH2 mutations in the NOTCH signaling pathway, resulting in multi-organ involvement including the liver, heart, lungs, kidneys, eyes, and skeletal system. Recognize that pruritus (itching) associated with chronic cholestasis in ALGS often serves as a critical indicator for orthotopic liver transplantation in affected children.Call Points: Pediatric and Adult Hepatology/Gastroenterology, Genetics, Pediatrics

N. Ca, Central Valley & Hawaii

Premarket and launch execution for two benign hematologic disorders, Cablivi (Caplacizumab IV, SC) and Cold Agglutinin Disease (CAD). Cablivi is a transformational treatment for acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening autoimmune blood disorder caused by a severe deficiency of the ADAMTS13 cleaving enzyme of Von Willebrand Factor (Factor VII, VWF), leading adhesion and consumption of platelets. Patients with aTTP experience acute and severe thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and organ occlusion/ischemia, often resulting in complications of thrombotic microangiopathy. Responsibilities include generating sales and establish Cablivi (Caplacizumab IV, SC) as the standard of care for aTTP to be initiated at the time of plasma exchange and immunosuppressive therapy.Management and development of key opinion leaders (KOLs) in Hematology, Hematology Pharmacists, Transfusion/Pathology. Identify new potential strategic speakers in the Northern California, Hawaii, and Central Valley regions. Call Points: Hematology/Oncology, Nephrology, Emergency Room (ER), Intensive Care Unit (ICU), Hospitalist/Intensivist, Transfusion/Hematopathology, and Inpatient Pharmacy.

N. Ca, Nv, Or, Wa, Id, Ak

Manager Key Academic Accounts and Centers of Excellence across a diverse 5 state region converting N. CA, WA, OR, NV, and AK. Proactively built awareness and provided comprehensive education on diagnosis and treatment for LAL-D and Hypophosphatasia, two ultra-rare, progressive, and life-threatening genetic disorders.Delivered specialized knowledge to targeted providers, emphasizing the importance of considering LAL-D in the differential diagnosis with more common chronic conditions in the diagnostic workup/evaluation as an alternate etiology of hepatic steatosis.Established and developed a PacNW Center of Excellence Care Team in collaboration with Alexion, encompassing Seattle Children's Hospital and Mary Bridge Children's Hospital. This initiative aimed to provide exceptional care, support and treatment for patients with these disorders.Collaborated with account leads and payer leads to support key Health Economics and Outcomes Research (HEOR) and algorithmic initiatives. These efforts facilitated risk stratification for testing and identification of patients suitable for treatment with Sebelipase Alfa, an innovative therapeutic option.Fostered the development of Key Opinion Leaders (KOLs) in the Pacific Northwest, forging seamless coordination between commercial efforts and support from Medical Science Liaisons (MSLs).Engaged with various hospital and office-based adult and pediatric sub-specialties, including multidisciplinary teams in cardiology, endocrinology, gastroenterology/hepatology, genetics, laboratory operations, lipidology, maternal-fetal medicine, neonatology, NICU, and pathology. Ensured comprehensive outreach across diverse medical domains to maximize impact and reach.By effectively executing these responsibilities, I contributed to the improved understanding, diagnosis, and treatment of HPP and LAL-D, positively impacting patient outcomes and quality of care.

San Francisco Bay Area

Institutional/Hospital Sales representative in launch of Praluent (Alirocumab) for patients not at LDL-C goal on statin therapy or statin intolerant and at high risk for ASCVD events. Developed inpatient protocols and discharge planning for patients in hospital.

San Francisco Bay Area

Pulmonary Arterial Hypertension WHO Group I covering the San Francisco Bay Area, Key academic centers and community education to raise awareness and appropriate diagnosis for Letairis (Ambrisentan, Endothelin Receptor Antagonist). Education to KOL’s on differential diagnosis of patients with WHO Group I. Cardiac Transplant Center, Academic Centers, Heart Failure Clinics, Pulmonology and Interventional Cardiology.

Sacramento, California, United States

Sacramento, California, United States